1 Ocak 2022 Dergi makalesi Açık Erişim

Erdogan, Ebru; Yalcin, Koray; Hemsinlioglu, Cansu; Sezgin, Aslihan; Seyis, Utku; Kancagi, Derya Dilek; Tastan, Cihan; Yurtsever, Bulut; Turan, Raife Dilek; Cakirsoy, Didem; Abanuz, Selen; Karakus, Gozde Sir; Elek, Muhammer; Bekoz, Huseyin Saffet; Gemici, Ali Ihsan; Sargin, Deniz; Arat, Mutlu; Ferhanoglu, Burhan; Pekguc, Ebru; Ornek, Serdar; Ornek, Serdar

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Erdogan, Ebru</dc:creator>
  <dc:creator>Yalcin, Koray</dc:creator>
  <dc:creator>Hemsinlioglu, Cansu</dc:creator>
  <dc:creator>Sezgin, Aslihan</dc:creator>
  <dc:creator>Seyis, Utku</dc:creator>
  <dc:creator>Kancagi, Derya Dilek</dc:creator>
  <dc:creator>Tastan, Cihan</dc:creator>
  <dc:creator>Yurtsever, Bulut</dc:creator>
  <dc:creator>Turan, Raife Dilek</dc:creator>
  <dc:creator>Cakirsoy, Didem</dc:creator>
  <dc:creator>Abanuz, Selen</dc:creator>
  <dc:creator>Karakus, Gozde Sir</dc:creator>
  <dc:creator>Elek, Muhammer</dc:creator>
  <dc:creator>Bekoz, Huseyin Saffet</dc:creator>
  <dc:creator>Gemici, Ali Ihsan</dc:creator>
  <dc:creator>Sargin, Deniz</dc:creator>
  <dc:creator>Arat, Mutlu</dc:creator>
  <dc:creator>Ferhanoglu, Burhan</dc:creator>
  <dc:creator>Pekguc, Ebru</dc:creator>
  <dc:creator>Ornek, Serdar</dc:creator>
  <dc:creator>Ornek, Serdar</dc:creator>
  <dc:date>2022-01-01</dc:date>
  <dc:description>Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products regarding their affordability and sustainability. In this preliminary study, the results of the first production and clinical data of an academic CAR-T cell (ISIKOK-19) trial in Turkey are presented.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/259959</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:259959</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>TURKISH JOURNAL OF HEMATOLOGY 39(3) 206-210</dc:source>
  <dc:title>Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>